Tele: 561.316.3330
Breaking Medical Device News

Monday, September 27, 2021
HomeMEDTRONIC plcNew Pediatric At-Home Study of MiniMed(TM) 670G System Demonstrates Positive Results in Children Ages 7 to 13

New Pediatric At-Home Study of MiniMed(TM) 670G System Demonstrates Positive Results in Children Ages 7 to 13

Data from this study was included in an FDA application in late January to seek future expansion of the current indication to include children 7-13 years of age. Medtronic is also evaluating the system in children 2-6 years of age and will present data from this trial at a future date. However, product labeling currently warns that the system may not be safe for children under age 7 or patients using less than 8 units of insulin per day. See http://bit.ly/670gRisks.

“It is incredibly rewarding on both a professional and personal level to evaluate a therapy that has the potential to alleviate the enormous weight of responsibility experienced by parents and caregivers of children with type 1 diabetes.” said Dr. Kevin Kaiserman, primary study investigator at the Southern California Diabetes Center. “I’m very pleased to see that the positive results observed in the pivotal trial studying older patients were also sustained in this study.”

The at-home, multi-center study enrolled 105 participants ages 7-13 and included a 2-week run-in phase, followed by a 3-month study phase. Over 15,353 patient days were included in the evaluation with 97 percent of participants opting to continue using the system as part of a Continued Access Program. Participants in the study were required to enter their mealtime carbohydrates and periodically calibrate the sensor.

“This important data shows that the MiniMed 670G system can lead to more time in the desired glucose target range in school-aged children, while it reduces both time spent in hypoglycemia and hyperglycemia,” said Francine Kaufman, M.D., chief medical officer of the Diabetes Group at Medtronic. “This hopefully should enable children with type 1 diabetes to decrease the risk of experiencing short and long term diabetes complications.”

A subset of data from this study of 7-13 year old patients, also presented at ATTD on Thursday, February 15, 2018, reinforced the significant benefits of the SmartGuard(TM) Suspend before low feature available in both the MiniMed 670G system and MiniMed(TM) 640G system. The MiniMed 640G system is approved for use outside of the U.S. but is not approved in the U.S. SmartGuard technology is the proprietary algorithm from Medtronic that powers its advanced MiniMed insulin pump systems. Each advancement in the company’s phased approach to developing a closed loop system enables increased automation of SmartGuard technology so the system takes on more of the work associated with daily diabetes management – helping to improve quality of life and overall glucose control for patients.

The MiniMed 670G system is the world’s first and only commercially available hybrid closed loop system and features the company’s new Guardian(TM) Sensor 3 and most advanced SmartGuard Auto Mode algorithm, which allows the system to automate the delivery of basal insulin to help maximize Time in Range throughout the day and night.

Time in Range
Time in Range refers to the percentage of time people with type 1 diabetes spend in the optimal glycemic range of 70-180 mg/dL. The goal with diabetes management is to increase time spent in this healthy range and to minimize high and low sugar levels, which can lead to both immediate and long-term complications such as damage to blood vessels – increasing the risk of coronary artery disease, heart attack, and stroke. Damage to blood vessels can also lead to loss of vision, kidney disease, and nerve problems. Increasing the “Time in Range” over the long-term can best be accomplished by using advances in diabetes therapies, like the MiniMed 670G system with SmartGuard technology, that automates basal insulin.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Tyber Medical Reaches Agreement to Acquire CatapultMD

Once the acquisition is complete, Tyber Medical will own and operate a combined 100,000-square feet of manufacturing space between its Pennsylvania headquarters and Florida-based facilities.

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy